BevCanna Enterprises

GEMINI THERAPEUTICS NASDAQGMTX STOCK QUOTE

https://geminitherapeutics.com/

LATEST NEWS FROM GEMINI THERAPEUTICS

Lightstone Ventures Raises $375 Million Fund

Gemini Therapeutics Announces Presentation of Preclinical Data at the 13th International Conference on Complement Therapeutics

Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at EURETINA 2021 Virtual

Gemini Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at Clinical Trials at the Summit

Gemini Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update

Gemini Therapeutics to Participate in the H.C. Wainwright Ophthalmology Conference

Gemini Therapeutics Announces Initial Data From Its Ongoing Phase 2a Study of GEM103 in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Gemini Therapeutics to Participate in the Jefferies Virtual Healthcare Conference

Gemini Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

Gemini Therapeutics Completes Enrollment in Phase 2a Study of GEM103 as an Add-On to Anti-VEGF Therapy for the Treatment of Wet AMD Patients at Risk for Progressive Vision Loss Due to Macular Atrophy

Gemini Therapeutics Announces Appointment of Georges Gemayel, Ph.D. as Chair of Board of Directors

Gemini Therapeutics Announces Presentation of Preclinical Data at 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Gemini Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Gemini Therapeutics Appoints Samuel Barone, M.D., as Chief Medical Officer

Gemini Therapeutics Reports Full Year 2020 Financial Results and Provides Business Update

Gemini Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference